Opt Health and Maximus both bundle a telehealth clinician with a prescription pathway, and both can raise a man's testosterone. They disagree about what else belongs in the product. Maximus scopes tightly to hormones and centers on enclomiphene, a treatment that stimulates the body's own production rather than replacing it. Opt Health runs a 55+ marker panel and treats testosterone as one lever among metabolic, thyroid, inflammatory, and nutrient ones. Price is close enough that scope, not cost, is the real decision.
The Verdict
What each platform actually is
Opt Health
Opt Health is an annual membership at roughly $3,000. It includes a 55+ biomarker panel — free and total testosterone, SHBG, LH, FSH, DHEA-S, estradiol and a full thyroid panel, alongside fasting insulin, HOMA-IR, HbA1c, ApoB, Lp(a), hsCRP, homocysteine, vitamin D, ferritin, omega-3 index, and liver, kidney and blood counts. A physician reads the panel in a one-on-one consult and builds a protocol from it. The same panel is repeated every 3–4 months and the protocol adjusted against it, with no per-draw charge. Phlebotomy is available at home in most markets. TRT, peptides, GLP-1 medications and supplement protocols are prescribed when the labs support them, and billed at medication cost above the membership.
Maximus
Maximus is a monthly hormone program for men, priced at roughly $150–$300 depending on which protocol fits, with a separate initial assessment of about $200–$400 covering labs and the physician review. Its defining protocol is enclomiphene, which raises testosterone by stimulating the hypothalamic-pituitary-gonadal axis instead of supplying the hormone from outside. In most enclomiphene protocols the medication itself is bundled into the monthly fee. Conventional TRT and related hormone protocols are also available, priced around $50–$150 monthly for the medication. Draws happen at a partner lab, and every follow-up panel is billed separately at roughly $100–$300. Metabolic, GLP-1 and peptide work sit outside the product.
Side by side on the standard rubric
The same nine criteria applied to both columns. The cells below the fold are where the two products stop resembling each other.
| Criterion | Opt Health | Maximus |
|---|---|---|
| Annual price (entry) | ~$3,000/yr membership | ~$150–$300/mo (~$1,800–$3,600/yr) + labs |
| Biomarkers (base panel) | 55+ (full spectrum) | Hormone-focused (limited) |
| Physician access | Bundled — one-on-one physician | Bundled — telehealth |
| Prescription pathway | TRT · peptides · GLP-1 · supplements | Enclomiphene · TRT · related |
| Retest cadence | Every 3–4 months | Per protocol |
| Ongoing reassessment | Care team + protocol adjustment | Telehealth clinician + dose adjustment |
| Draw type | At-home phlebotomy | Partner lab |
| Hidden costs | Prescription medications | Lab work billed separately |
| Public litigation | None publicly identified (as of Aug 2026) | None publicly identified (as of Aug 2026) |
| Best for | Full optimization for adults over 40 | Men who want testosterone up while preserving fertility |
What each actually costs
| Cost layer | Opt Health | Maximus |
|---|---|---|
| Entry price | ~$3,000/yr membership | ~$150–$300/mo (~$1,800–$3,600/yr) plus a ~$200–$400 initial assessment |
| Typical add-ons | TRT ~$50–$200/mo · GLP-1 ~$200–$400/mo compounded ($800+ brand-name) · peptides ~$150–$400/mo | Follow-up labs ~$100–$300 per panel · TRT medication ~$50–$150/mo if prescribed alongside or instead of enclomiphene |
| Realistic year-one all-in | $3,000–$6,000+ depending on which protocols are prescribed | $1,800–$3,600+ before labs; four to six follow-up panels during an active adjustment year add roughly $400–$1,800 |
| Year two (ongoing) | ~$3,000 membership, plus medication at cost | ~$1,800–$3,600; the ~$200–$400 initial assessment does not repeat, but lab work continues at whatever cadence the protocol needs |
| What is billed separately | All medications and supplement protocols | All lab work, plus any medication outside the enclomiphene protocol (conventional TRT, ancillaries) |
Opt Health charges one annual number that already contains the labs. Physician time, the base panel, and every 3–4 month re-run are inside the ~$3,000, and none of them meter. Year two costs the same, because there is no one-time onboarding fee to fall away. Medication is the only variable: TRT alone adds roughly $600–$2,400 over twelve months, a compounded GLP-1 roughly $2,400–$4,800, peptides roughly $1,800–$4,800. That is how a $3,000 membership becomes a $6,000-plus year, and it is also why a member on no medication pays the same as a member on three.
Maximus splits the bill in the opposite direction: the medication is often inside the monthly fee and the labs are outside it. Year one starts around $2,000 at the low end — a $200 assessment plus twelve months at $150 — and reaches $3,600 or more on a higher-tier protocol. Follow-up panels every 8–12 weeks during active titration mean four to six draws at $100–$300 each, adding $400–$1,800 that the monthly price never shows. Year two drops the assessment fee but keeps the lab line, so the ongoing number depends entirely on how often your protocol is still moving.
Where Opt Health leads
- Panel scope. 55+ markers spanning metabolic, thyroid, cardiovascular, inflammatory and nutrient categories alongside the hormone set, from one draw.
- Labs inside the price. Every reassessment panel is covered by the membership, so the number of draws in a year is a clinical decision rather than a spending one.
- Prescribing breadth. GLP-1 medications, peptides and supplement protocols sit in the same pathway as hormone treatment, under one prescriber.
- At-home draws. Phlebotomy comes to the member in most markets rather than requiring a trip to a partner lab for each panel.
- Fixed reassessment calendar. The full panel repeats every 3–4 months on a set schedule rather than being re-scoped protocol by protocol.
Where Maximus leads
- Enclomiphene as the core protocol. The platform is built around a treatment that raises testosterone by stimulating the body's own production rather than replacing the hormone.
- Fertility preservation. Enclomiphene preserves LH and FSH signaling and testicular function; exogenous testosterone replacement typically suppresses both.
- Medication bundled into the fee. In most Maximus enclomiphene protocols the drug is included in the monthly price rather than billed on top of it.
- Lower amount committed up front. A first month costs roughly $350–$550 including the assessment, so the sum at risk before you see a result is a few hundred dollars.
- Lab timing matched to titration. Follow-up panels run every 8–12 weeks during active adjustment, which is the window a hormone marker needs to settle after a dose change.
Trade-offs to weigh
Opt Health trade-offs
- Large sum committed before any result. The membership is priced annually at ~$3,000, against a Maximus first month of roughly $350–$550 — so the cost of discovering the product is not a fit is very different.
- Not built around the fertility question. Enclomiphene may be prescribed when clinically indicated, but the platform is not organized around that protocol, and nothing in the membership price signals how much depth it carries on it.
- Poor value for a single-marker problem. If testosterone is the only thing you want treated, most of the 55+ panel and most of the fee is spent measuring questions you did not ask.
- Telehealth-only, cash-pay, medication on top. No in-person exam exists at any tier, no insurance channel exists, and TRT, GLP-1s and peptides are all billed at cost above the ~$3,000.
Maximus trade-offs
- Hormone-focused panel. Metabolic, thyroid, inflammatory and nutrient markers sit outside the core product, so a non-hormonal driver of low energy — low ferritin, poor insulin sensitivity, an under-treated thyroid — can go unmeasured.
- Open-ended lab spend. At $100–$300 a panel every 8–12 weeks, an active year adds $400–$1,800 that the advertised monthly price does not include.
- Retest cadence set per protocol. Flexibility cuts both ways: with no fixed schedule, both the frequency of measurement and the size of the lab bill are decided case by case.
- Narrow prescribing scope. Enclomiphene, TRT and related hormone protocols only. Weight, metabolic or peptide work requires a second provider and a second relationship.
Who should pick each
Pick Opt Health if: you are over 40, several things feel wrong at once — energy, weight, sleep, libido — and you do not yet know which marker explains which symptom. You want one physician looking at hormones, metabolic function and inflammation from the same draw, and you would rather pay a fixed annual number than approve a lab charge every eight weeks. You have no immediate fertility constraint on the treatment choice.
Pick Maximus if: you are a man whose testosterone is the specific problem, and you either want children in the next few years or do not want to suppress your own production for any other reason. You are comfortable traveling to a partner lab and paying for panels line by line. You already have a physician handling anything outside hormones, so the narrow scope costs you nothing you were not already covering.
Who should pick neither
Both products presume you have already established that testosterone is low. Neither is a diagnostic starting point, and each charges a treatment-relationship price for what may still be a measurement question. Four alternatives cover the situations where that presumption does not hold.
- You want the data before the relationship. Function Health sells a wide panel without a prescribing clinician attached, at a fraction of either fee.
- You want conventional TRT and have no fertility concern. Hone Health prescribes conventional testosterone therapy at an entry price below both platforms on this page, without the enclomiphene specialization you would be paying for.
- Fertility is the actual worry. A semen analysis measures fertility directly; a testosterone panel does not. In-network urology or reproductive endocrinology covers that workup, and it answers a question neither platform's blood panel can.
- Fatigue with no measured hormone deficit. An in-network primary care workup — TSH, ferritin, HbA1c, vitamin D, a lipid panel — costs a copay and frequently ends the search before any membership is bought.
Can you use both?
Stacked, the two run roughly $4,800–$6,600 in year one before medication and lab work, and the overlap is substantial. Both include a hormone panel, both include a telehealth prescriber, and both can write testosterone therapy. The specific hazard is not cost — it is two clinicians dosing the same axis from different panels drawn on different weeks. Enclomiphene stimulates LH and FSH; exogenous testosterone suppresses them. Run without coordination, the two protocols work against each other, and neither prescriber sees the combined effect in their own labs.
The defensible version is deliberate and disclosed. A man already on Opt Health for metabolic work and a GLP-1 protocol may want enclomiphene from the specialist while keeping the broad program — that is coherent, provided both prescribers know about each other and one of them owns the hormone decisions outright. Send each platform the other's most recent panel, and name which clinician is titrating testosterone. If you are unwilling to do that administrative work every quarter, run one.
What the rubric does not capture
A ten-row table cannot show what the consult is about. At Maximus the conversation is scoped to the protocol: dose, side effects, the next panel. At Opt Health it starts from a full history and a panel that reaches well past hormones, which means more ground covered and more time spent on markers you may not have been worried about. Neither structure is superior — but they reward different members. Someone who wants a narrow, repeatable check-in will find the broad consult diffuse, and someone with four overlapping complaints will find the narrow one incomplete.
Month six differs more than month one does. On a stable enclomiphene protocol, a Maximus member may go long stretches with little happening — the per-protocol cadence means measurement slows once the dose settles, and the monthly fee keeps running. An Opt Health member gets a full panel whether or not anything changed, which for a stable member can feel like paying to confirm that nothing moved. The same design that makes one platform efficient during titration makes it quiet during maintenance, and vice versa.
The clinical detail neither product page leads with: enclomiphene only works if the testes can respond. It acts upstream, prompting the pituitary to signal harder, so men with primary hypogonadism — where the deficit is testicular rather than in the signaling — do not respond to it the way men with secondary hypogonadism do. LH and FSH on the initial panel are what separate those two pictures, which makes the assessment draw more decisive than the monthly price. Prior anabolic steroid use, long-standing TRT, and an SSRI already affecting libido and energy all change how that first panel should be read — raise each of them before either platform builds a protocol.
Frequently Asked Questions
Is Opt Health or Maximus better?
They answer different questions. Maximus is built around enclomiphene, for men who want testosterone raised without suppressing their own production. Opt Health treats testosterone as one input inside a 55+ marker program that also covers metabolic, thyroid, inflammatory, and nutrient drivers. If fertility preservation is the deciding factor, that is a Maximus question. If low testosterone is one of four things that look wrong, that is an Opt Health question.
Does Opt Health offer enclomiphene?
Enclomiphene may be prescribed at Opt Health when clinically indicated, alongside conventional TRT and other hormone protocols. Maximus is the platform built specifically around it, and bundles the medication into most of its monthly protocols rather than billing it separately.
Which one is more expensive?
Similar range at full utilization. Opt Health is ~$3,000/yr all-in for the membership. Maximus is $1,800–$3,600/yr plus lab work, which adds roughly $400–$1,800 during a year of active dose adjustment. Once labs and any additional medication are counted, the two land in comparable territory — the difference is scope, not price.
Will insurance, HSA, or FSA cover either?
Neither platform bills insurance; both are cash-pay. HSA and FSA reimbursement is often possible and has to be confirmed with your plan administrator. One practical note: Maximus lab work is billed as a separate line item, which makes it easier to submit piecemeal against an FSA balance than a single annual membership charge.
How long until testosterone actually moves?
Hormone markers respond within weeks of starting either an enclomiphene or a TRT protocol, but a reading that is worth titrating against usually needs 8–12 weeks. Maximus schedules follow-up panels in roughly that window during active adjustment. Opt Health's 3–4 month reassessment lands at the outer edge of it.
What if I only want testosterone treated?
Then most of an Opt Health membership is spent on markers outside your question, and a hormone-first platform fits better. Maximus is the fit if you want to preserve fertility. If you have no fertility concern and want conventional TRT, Hone Health runs a lower entry price than either platform compared here.
Can I switch from one to the other later?
Yes. Expect the receiving platform to run its own panel before writing anything, so budget for repeat labs. The clinical caution is the direction of the switch: moving from enclomiphene to conventional TRT suppresses the axis enclomiphene was stimulating, and moving the other way means waiting for your own production to recover. Neither transition is instant, and both should be planned with the prescriber, not around them.
Do I need a doctor already?
No. Both platforms include the prescribing clinician. But if you have an existing physician managing anything hormone-adjacent — thyroid medication, antidepressants, fertility treatment — tell both sides. Enclomiphene and TRT both act on the same axis a fertility specialist may already be managing, and two prescribers working from different panels is how doses get stacked by accident.